Evidence map›Paper›PMID 29666812›Full record

ReviewAnnals of translational medicine2018

Tumor progression: the neuronal input.

Marco Arese, Federico Bussolino, Margherita Pergolizzi, Laura Bizzozero, Davide Pascal

Open access · hybridAbstract readReview
In one paragraph

Review in Annals of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Review
  3. Tumor Innervation: From Bystander to Emerging Therapeutic Target for Cancer.International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. The tumor-nerve circuit in breast cancer.Cancer metastasis reviews · 2023
    Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Tumour invasion and dissemination.Biochemical Society transactions · 2022
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Marco AreseDepartment of Oncology, University of Torino Medical School, Candiolo Cancer Institute - FPO, IRCCS, Turin, Italy.
Federico BussolinoDepartment of Oncology, University of Torino Medical School, Candiolo Cancer Institute - FPO, IRCCS, Turin, Italy.
Margherita PergolizziDepartment of Oncology, University of Torino Medical School, Candiolo Cancer Institute - FPO, IRCCS, Turin, Italy.
Laura BizzozeroDepartment of Oncology, University of Torino Medical School, Candiolo Cancer Institute - FPO, IRCCS, Turin, Italy.
Davide PascalDepartment of Oncology, University of Torino Medical School, Candiolo Cancer Institute - FPO, IRCCS, Turin, Italy.
Candiolo Cancer Institute · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the challenges of cancer is its heterogeneity and rapid capacity to adapt. Notwithstanding significant progress in the last decades in genomics and precision medicine, new molecular targets and therapies appear highly necessary. One way to approach this complex problem is to consider cancer in the context of its cellular and molecular microenvironment, which includes nerves. The peripheral nerves, the topic of this review, modulate the biological behavior of the cancer cells and influence tumor progression, including the events related to the metastatic spread of the disease. This mechanism involves the release of neurotransmitters directly into the microenvironment and the activation of the corresponding membrane receptors. While this fact appears to complicate further the molecular landscape of cancer, the neurotransmitters are highly investigated molecules, and often are already targeted by well-developed drugs, a fact that can help finding new therapies at a fraction of the cost and time needed for new medicines (through the so-called drug repurposing). Moreover, the modulation of tumor progression by neurotransmitters can probably explain the long-recognized effects of psychological factors on the burden of cancer. We begin with an introduction on the tumor-nervous-connections and a description of the perineural invasion and neoneurogenesis, the two most important interaction patterns of cancer and nerves. Next, we discuss the most recent data that unequivocally demonstrate the necessity of the nervous system for tumor onset and growth. We introduce the molecular players of the tumor-nervous-connections by citing the role of three main families: neurotropic factors, axon guidance molecules, and neurotransmitters. Finally, we review the role the most important neurotransmitters in tumor biology and we conclude by analyzing the significance of the presented data for cancer therapy, with all the potential advantages and caveats.

Indexed as

drug repurposingneurotransmitterstumor microenvironmentTumor-nervous connections (TNCs)

Identifiers

PMID29666812
PMCPMC5890045
OpenAlexW2783578372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.